Manuel Battegay

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint [Travel in a smaller world]
    M Battegay
    Klinik für Infektiologie, Universitätskliniken Basel, Schweiz
    Internist (Berl) 45:639-40. 2004
  2. ncbi request reprint Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma
    Manuel Battegay
    Division of Infectious Diseases, Department of Internal Medicine and Research, University Hospital of Basel, Basel, Switzerland
    Antivir Ther 9:453-9. 2004
  3. pmc Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition
    Erik Mossdorf
    St Francis Designated District Hospital, Ifakara, United Republic of Tanzania
    BMC Infect Dis 11:98. 2011
  4. ncbi request reprint Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
    M Battegay
    Basel Centre for HIV Research, Outpatient Department of Internal Medicine, University Hospital Basel, Switzerland
    HIV Med 2:35-42. 2001
  5. ncbi request reprint [Therapy of severe fungal infections]
    M Battegay
    Abteilung für Infektiologie, Universitätskliniken Basel, Switzerland
    Internist (Berl) 44:1549-56. 2003
  6. doi request reprint Antiretroviral therapy of late presenters with advanced HIV disease
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Antimicrob Chemother 62:41-4. 2008
  7. ncbi request reprint [Primary HIV infection]
    M Battegay
    Klinik für Infektiologie, Universitatsspital Basel
    Ther Umsch 61:609-12. 2004
  8. ncbi request reprint [The value of clinical infectology]
    M Battegay
    Klinik für Infektiologie, Universitatsspital Basel, Schweiz
    Internist (Berl) 46:623-9. 2005
  9. doi request reprint Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Swiss Med Wkly 139:564-70. 2009
  10. ncbi request reprint [Parasitic diseases]
    M Battegay
    Klinik für Infektiologie und Spitalhygiene, Universitatsspital, Petersgraben 4, 4031, Basel
    Internist (Berl) 47:785. 2006

Collaborators

Detail Information

Publications148 found, 100 shown here

  1. ncbi request reprint [Travel in a smaller world]
    M Battegay
    Klinik für Infektiologie, Universitätskliniken Basel, Schweiz
    Internist (Berl) 45:639-40. 2004
  2. ncbi request reprint Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma
    Manuel Battegay
    Division of Infectious Diseases, Department of Internal Medicine and Research, University Hospital of Basel, Basel, Switzerland
    Antivir Ther 9:453-9. 2004
    ..This case report demonstrates the close association of EBVL and AITL and a beneficial effect of antiviral therapy at an initial stage of disease manifestation...
  3. pmc Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition
    Erik Mossdorf
    St Francis Designated District Hospital, Ifakara, United Republic of Tanzania
    BMC Infect Dis 11:98. 2011
    ..Data on combination antiretroviral therapy (cART) in remote rural African regions is increasing...
  4. ncbi request reprint Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
    M Battegay
    Basel Centre for HIV Research, Outpatient Department of Internal Medicine, University Hospital Basel, Switzerland
    HIV Med 2:35-42. 2001
    ..To assess the short-term and long-term effect of a combination of saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed protease inhibitor-naive patients...
  5. ncbi request reprint [Therapy of severe fungal infections]
    M Battegay
    Abteilung für Infektiologie, Universitätskliniken Basel, Switzerland
    Internist (Berl) 44:1549-56. 2003
    ..Nevertheless, promising results indicate that certain combinations of antifungals may enhance prognosis of refractory fungal infections with a so far very serious prognosis...
  6. doi request reprint Antiretroviral therapy of late presenters with advanced HIV disease
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Antimicrob Chemother 62:41-4. 2008
    ..We encourage physicians to perform HIV testing more frequently in order to detect HIV-infected individuals in time...
  7. ncbi request reprint [Primary HIV infection]
    M Battegay
    Klinik für Infektiologie, Universitatsspital Basel
    Ther Umsch 61:609-12. 2004
    ..Small studies may indicate that early therapy which is followed by a stop of antiretroviral therapy after one to two years may be followed by a better control of viremia...
  8. ncbi request reprint [The value of clinical infectology]
    M Battegay
    Klinik für Infektiologie, Universitatsspital Basel, Schweiz
    Internist (Berl) 46:623-9. 2005
    ..This article highlights the clinical work of infectious diseases specialists in an interdisciplinary setting and describes there value to patients and hospitals...
  9. doi request reprint Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Swiss Med Wkly 139:564-70. 2009
    ..The changing pattern of HIV-associated diseases may indicate the need for specific preventive measures in this population...
  10. ncbi request reprint [Parasitic diseases]
    M Battegay
    Klinik für Infektiologie und Spitalhygiene, Universitatsspital, Petersgraben 4, 4031, Basel
    Internist (Berl) 47:785. 2006
  11. ncbi request reprint Late presentation of HIV-infected individuals
    Manuel Battegay
    Division of Infectious Diseases Et Hospital Epidemiology, University Hospital Basel, Switzerland
    Antivir Ther 12:841-51. 2007
    ....
  12. ncbi request reprint [The 3' by 5' WHO/UNAIDS initiative--can 3 million people obtain HIV therapies by the end of 2005]
    M Battegay
    Praxis (Bern 1994) 94:1887-9. 2005
  13. doi request reprint [Commentary on the STROBE statement. A checklist for observational studies improves transparency]
    M Battegay
    Klinik für Infektiologie und Spitalhygiene, Universitatsspital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Internist (Berl) 49:694. 2008
  14. ncbi request reprint Immunological recovery and antiretroviral therapy in HIV-1 infection
    Manuel Battegay
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Lancet Infect Dis 6:280-7. 2006
    ..In addition, immune reconstitution disease, an inflammatory syndrome associated with immunological recovery occurring days to weeks after the start of antiretroviral therapy, is briefly described...
  15. ncbi request reprint Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    AIDS 21:2201-7. 2007
    ....
  16. doi request reprint Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008
    Luigia Elzi
    University Hospital Basel, Switzerland
    Arch Intern Med 170:57-65. 2010
    ..Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence...
  17. pmc Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure
    Pedram Sendi
    Division of Infectious Diseases and Hospital Epidemiology, Basel University Hospital, Basel, Switzerland
    PLoS ONE 2:e173. 2007
    ..We estimated the clinical effect, cost and cost-effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure...
  18. ncbi request reprint Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
    Jim Young
    Institut für klinisehe Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:585-91. 2005
    ..We report on medium-term lipid profiles (up to 5 years) for antiretroviral-naive patients starting NNRTI- and PI-based HAART in the Swiss HIV Cohort Study...
  19. doi request reprint CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
    ....
  20. doi request reprint Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Clin Infect Dis 46:1299-309. 2008
    ..We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study...
  21. doi request reprint Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
    Jim Young
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    AIDS 26:567-75. 2012
    ....
  22. doi request reprint Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy
    Jim Young
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    J Clin Epidemiol 62:632-41. 2009
    ..Hierarchical modeling has been proposed as a solution to the multiple exposure problem. We estimate associations between metabolic syndrome and different components of antiretroviral therapy using both conventional and hierarchical models...
  23. ncbi request reprint Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Clin Infect Dis 41:361-72. 2005
    ..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
  24. ncbi request reprint CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    Antivir Ther 12:889-97. 2007
    ..This study aimed to identify predictive factors for long-term CD4+ T-cell increase in treatment-naive patients starting combination antiretroviral therapy (cART)...
  25. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
    ..Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort...
  26. doi request reprint Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 15:413-23. 2010
    ..We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability...
  27. ncbi request reprint Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
    Arch Intern Med 167:1782-90. 2007
    ..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
  28. ncbi request reprint Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
    Jim Young
    Institut für Klinische Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:73-81. 2005
    ..Our objective is to show whether such associations are more or less likely for patients on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART...
  29. doi request reprint Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, ETH Zurich, Zurich, Switzerland
    Clin Infect Dis 48:979-87. 2009
    ..We attempted to assess the prevalence and dynamics of resistance in a highly representative patient cohort from Switzerland...
  30. ncbi request reprint TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents
    Gerd Laifer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    Am J Med 120:350-6. 2007
    ..Active screening programs are likely to change the clinical presentation of TB, but the extent of the difference between immigrant and resident populations has not been studied prospectively...
  31. ncbi request reprint Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
    Gilbert R Kaufmann
    Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Antivir Ther 9:263-74. 2004
    ..Information about the virological response to sequential highly active antiretroviral therapy (HAART) for HIV infection is limited. The virological response to four consecutive therapies was evaluated in the Swiss HIV Cohort...
  32. ncbi request reprint Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, CH 4056 Basel, Switzerland
    J Acquir Immune Defic Syndr 41:385-92. 2006
    ..Adherence is one of the most crucial issues in the clinical management of HIV-infected patients receiving antiretroviral therapy (ART)...
  33. ncbi request reprint Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study
    Anna Conen
    Divison of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Antivir Ther 14:349-57. 2009
    ..Here, we aimed to study self-reported alcohol consumption and to determine its association with adherence to antiretroviral therapy (ART) and HIV surrogate markers...
  34. doi request reprint Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Clin Trials 10:207-14. 2009
    ..We aimed to evaluate the efficacy and the impact of discontinuing and/or switching enfuvirtide on virologic and clinical parameters in clinical practice...
  35. doi request reprint Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection
    Helen Kovari
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Clin Infect Dis 50:502-11. 2010
    ..Chronic liver disease in human immunodeficiency virus (HIV)-infected patients is mostly caused by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult to diagnose...
  36. doi request reprint Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study
    Anna Conen
    Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Aarau, Aarau, Switzerland Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Clinic for Infectious Diseases, University Hospital Berne, University of Berne, Berne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Geneva, University of Geneva, Geneva, Switzerland Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland and Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland
    J Acquir Immune Defic Syndr 64:472-8. 2013
    ..The authors investigated the association between self-reported alcohol consumption and HIV surrogate markers in both treated and untreated individuals...
  37. ncbi request reprint Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
    Annelies S Zinkernagel
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Antivir Ther 11:131-42. 2006
    ....
  38. pmc Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e27463. 2011
    ..Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are debated...
  39. pmc Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study
    Jan Fehr
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Transl Med 9:14. 2011
    ..The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients...
  40. doi request reprint The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    J Infect Dis 204:1095-103. 2011
    ..By analyzing human immunodeficiency virus type 1 (HIV-1) pol sequences from the Swiss HIV Cohort Study (SHCS), we explored whether the prevalence of non-B subtypes reflects domestic transmission or migration patterns...
  41. doi request reprint Ageing with HIV: medication use and risk for potential drug-drug interactions
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    J Antimicrob Chemother 66:2107-11. 2011
    ..To compare the use of co-medication, the potential drug-drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥ 50 years or <50 years...
  42. doi request reprint Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 57:24-31. 2011
    ..Nucleoside reverse transcriptase inhibitors (NRTIs) are often administered in salvage therapy even if genotypic resistance tests (GRTs) indicate high-level resistance, but little is known about the benefit of these additional NRTIs...
  43. doi request reprint Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study
    Tracy R Glass
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    J Acquir Immune Defic Syndr 54:197-203. 2010
    ..Adherence to combination antiretroviral therapy (cART) is a dynamic process, however, changes in adherence behavior over time are insufficiently understood...
  44. ncbi request reprint Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 13:77-85. 2008
    ..The aim of this study was to explore the predictive value of longitudinal self-reported adherence data on viral rebound...
  45. pmc JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, CH 4031 Basel, Switzerland
    J Virol 83:4404-11. 2009
    ..JCV-specific T-cell and IgG responses may serve as prognostic markers for patients at risk...
  46. ncbi request reprint Is unsafe sexual behaviour increasing among HIV-infected individuals?
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    AIDS 18:1707-14. 2004
    ..The number of new diagnoses of HIV infection is rising in the northwestern hemisphere and it is becoming increasingly important to understand the mechanisms behind this trend...
  47. ncbi request reprint CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    ..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
  48. doi request reprint Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
    Barbara Hasse
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1130-9. 2011
    ..We studied the influence of aging on the epidemiology of non-AIDS diseases in the Swiss HIV Cohort Study...
  49. doi request reprint Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV
    Jim Young
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    Antivir Ther 14:771-9. 2009
    ..It is uncertain which therapy is more effective for patients starting therapy with an advanced infection...
  50. doi request reprint Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Basel, Basel, Switzerland
    Clin Infect Dis 48:1459-66. 2009
    ..We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996...
  51. pmc Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis
    Dominik Mertz
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    BMC Infect Dis 8:42. 2008
    ..Infectious disease is often the reason for intravenous drug users being seen in a clinical setting. The objective of this study was to evaluate the appropriateness of treatment and outcomes for this patient population in a hospital setting...
  52. ncbi request reprint Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study
    Tracy R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    HIV Clin Trials 8:77-85. 2007
    ..Based on a health care system approach, we investigated predictors for normalization of dyslipidemia in HIV-infected individuals receiving ART...
  53. doi request reprint Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
    Reto Nuesch
    Division of Infectious Diseases, Hirslanden Klinik St Anna, Lucerne, Switzerland Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital of St Gallen, St Gallen, Switzerland Division of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland and Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland
    J Acquir Immune Defic Syndr 62:396-404. 2013
    ..We modeled blood pressure over time and the risk of cardiovascular events in hypertensive HIV-infected individuals...
  54. pmc Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study
    Jim Young
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, Basle, CH 4031, Switzerland
    BMJ 328:15. 2004
    ..To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART)...
  55. doi request reprint Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland
    Clin Infect Dis 54:131-40. 2012
    ....
  56. doi request reprint Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania
    Erik Mossdorf
    St Francis Designated District Hospital, Ifakara, United Republic of Tanzania
    Trop Med Int Health 15:567-73. 2010
    ..To evaluate the impact of a national HIV voluntary counselling and testing (VCT) campaign on presentation to HIV care in a rural population in Tanzania...
  57. doi request reprint Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    Sara Gianella
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    Antivir Ther 16:535-45. 2011
    ..Early initiation of combination antiretroviral therapy (ART) during primary HIV-1 infection may prevent the establishment of large viral reservoirs, possibly resulting in improved control of plasma viraemia rebound after ART cessation...
  58. doi request reprint Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    AIDS 25:441-51. 2011
    ..Interruptions of ART are still frequent. The long-term effect on CD4 T-cell recovery and clinical events remains unknown...
  59. pmc Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    BMC Infect Dis 11:319. 2011
    ..Interferon-gamma release assays (IGRA) are more specific than the tuberculin skin test (TST) for the diagnosis of Mycobacterium tuberculosis infection. Data on sensitivity are controversial in HIV infection...
  60. doi request reprint Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors
    Annette Audigé
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
    AIDS Res Hum Retroviruses 26:997-1005. 2010
    ..The lack of an effect of ART on CD4 density implies a persistent dysfunctional immune response by uncontrolled HIV infection...
  61. doi request reprint Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland
    Roger D Kouyos
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 201:1488-97. 2010
    ..Sequence data from resistance testing offer unique opportunities to characterize the structure of human immunodeficiency virus (HIV) infection epidemics...
  62. doi request reprint Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 54:51-8. 2010
    ..This prospective study aimed to characterize the virologic and immunologic changes during monotherapy with lamivudine (3TC) in patients with limited options for a fully suppressive new therapy...
  63. ncbi request reprint Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
    Urs Karrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Switzerland
    AIDS 19:1987-94. 2005
    ..This effect might be related to ddI toxicity since ddI exposure is substantially increased by TDF...
  64. pmc The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients
    Niko Beerenwinkel
    Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
    PLoS Comput Biol 9:e1003203. 2013
    ..Thus, the IGB to regimen is a novel data-derived predictor of treatment outcome that has potential to improve the interpretation of genotypic drug resistance tests. ..
  65. ncbi request reprint Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients
    Heiner C Bucher
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Kantonsspital Basel, Switzerland
    AIDS 17:2451-9. 2003
    ..To evaluate the efficacy and safety of simplified maintenance therapy (SMT) compared with continued protease inhibitor (PI) therapy...
  66. ncbi request reprint Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Blood 104:1784-92. 2004
    ..In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1-infected individuals and reflected the patients' ability to decrease viral set points...
  67. doi request reprint Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study
    Heiner C Bucher
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    J Acquir Immune Defic Syndr 60:135-42. 2012
    ..We investigated the association of highly atherogenic small dense low-density lipoproteins (LDLs) and apolipoprotein B and coronary events in HIV-infected individuals receiving antiretroviral therapy...
  68. pmc Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy
    Tracy R Glass
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Basel, Switzerland
    PLoS ONE 7:e29186. 2012
    ..However, some patients remain virologically suppressed despite suboptimal adherence. We hypothesized that this could result from host genetic factors influencing drug levels...
  69. doi request reprint Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy
    Heiner C Bucher
    Basel Institute for Clinical Epidemiology and Biostatistics, Basel, Switzerland
    Antivir Ther 15:31-40. 2010
    ..Computerized clinical decision support systems have been advocated to improve the management of patients at risk for CHD but it is unclear whether such systems reduce patients' risk for CHD...
  70. ncbi request reprint A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
    Catherine Fagard
    Division of Infectious Diseases, Geneva Unmiversity Hospital, 1211 Geneva 14, Switzerland
    Arch Intern Med 163:1220-6. 2003
    ..Many patients who started HAART earlier in their disease course than is currently recommended would like to discontinue, but it is unknown whether it is safe to do so...
  71. ncbi request reprint A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Mathew Simcock
    Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
    Antivir Ther 11:305-14. 2006
    ..To assess the impact of antiretroviral therapy optimized by genotypic antiretroviral resistance testing (GRT) on healthcare costs over a 2-year period in patients after antiretroviral treatment failure...
  72. ncbi request reprint Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival
    Cornelia Staehelin
    Division of Infectious Diseases, University Hospital Berne, Berne, Switzerland
    AIDS 17:2237-44. 2003
    ....
  73. ncbi request reprint Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes
    Natasha Hansjee
    Institute for Medical Microbiology, University of Basel, Division of Infectious Diseases, Department of Internal Medicine, University Hospital Basel, Switzerland
    J Acquir Immune Defic Syndr 36:671-7. 2004
    ..The significant relationship between residual T-lymphocyte apoptosis and CD4 T-cell recovery suggests that persistent apoptosis may impede immune restoration...
  74. doi request reprint Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children
    Christoph Rudin
    Division of Infectious Diseases, University Children s Hospital, Basel, Switzerland
    Pediatr Infect Dis J 27:431-7. 2008
    ..To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced, initially protease inhibitor (PI)-naive, human immunodeficiency virus (HIV)-1-infected children...
  75. ncbi request reprint Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Switzerland
    Lancet 353:863-8. 1999
    ..The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice...
  76. ncbi request reprint A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  77. ncbi request reprint Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study
    Luigia Elzi
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    AIDS 20:129-31. 2006
    ..Pharmacokinetic data indicated therapeutic concentrations for both protease inhibitors in most patients...
  78. doi request reprint Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
    M Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    HIV Med 9:397-405. 2008
    ..To investigate delayed HIV diagnosis and late initiation of antiretroviral therapy (ART) in the Swiss HIV Cohort Study...
  79. doi request reprint Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children
    Christoph Rudin
    Division of Infectious Diseases, University Children s Hospital, Basel, Switzerland
    Arch Dis Child 95:478-81. 2010
    ..To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children...
  80. doi request reprint Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
    R Weber
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Raemistrasse 100, Zurich CH 8091, Switzerland
    HIV Med 10:407-16. 2009
    ..Design A prospective observational study of all participants in the Swiss HIV Cohort Study followed between 1997 and 2006 was carried out...
  81. ncbi request reprint Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
    T R Glass
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland
    HIV Med 7:404-10. 2006
    ..We evaluated changes in the prevalence of cardiovascular risk factors (CVRFs) and 10-year risk of CHD in a large cohort of HIV-infected individuals...
  82. ncbi request reprint Evaluation of unstructured medical school examinations: prospective observational study
    Andreas Zeller
    Medical Outpatient Department, University Hospital, Basel, Switzerland
    Swiss Med Wkly 133:184-7. 2003
    ....
  83. ncbi request reprint Immune reconstitution in HIV-infected patients
    Hans H Hirsch
    Division of Infectious Diseases, University Hospital Basel, Switzerland
    Clin Infect Dis 38:1159-66. 2004
    ..Specific antimicrobial therapy, nonsteroidal anti-inflammatory drugs, and/or steroids for managing immune reconstitution syndrome should be considered...
  84. ncbi request reprint Chest pain after travel to the tropics
    Luigia Elzi
    Division of Infectious Diseases University Hospital Basel CH 4002 Basel, Switzerland
    Lancet 363:1198. 2004
  85. doi request reprint Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals
    Simone Ehrhard
    Department of Biomedicine, Institute for Medical Microbiology, University of Basel, Basel, Switzerland
    Hum Pathol 40:1427-33. 2009
    ....
  86. ncbi request reprint Protease inhibitor-sparing simplified maintenance therapy: a need for perspective
    Heiner C Bucher
    Basel Institute for Clinical Epidemiology, Division of Infectious Diseases, University Hospital Basel, CH 4031 Basel, Switzerland
    J Antimicrob Chemother 54:303-5. 2004
    ..The advent of simpler formulations for all drug classes, and new PIs with less metabolic toxicity, is likely to reshape completely the role of SMT...
  87. ncbi request reprint Optimising the performance of an outpatient setting
    Pedram Sendi
    Institute for Medical Technology Assesment, Erasmus University, Rotterdam, The Netherlands
    Swiss Med Wkly 134:44-9. 2004
    ..The optimum mix of human resources may be determined using discrete-event simulation...
  88. pmc HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts
    Olivier Gasser
    Immunobiology Laboratory, Department of Research, University Hospital Basel, Basel, Switzerland
    PLoS Med 4:e96. 2007
    ....
  89. pmc Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study
    Julian Mettler
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    BMC Infect Dis 7:21. 2007
    ....
  90. ncbi request reprint Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study
    Christoph Hess
    Department of Research, Immunonephrology Laboratory, University Hospital Basel, Basel, Switzerland
    Lancet 359:2230-4. 2002
    ..In vitro, erythrocytes bind HIV-1 immune complexes, so we tested for a circulating pool of HIV-1 associated with erythrocytes in people with HIV-1 infection...
  91. ncbi request reprint Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case
    Anne Catherine Guex
    Basel Center for HIV Research, Outpatient Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Dis Colon Rectum 45:977-8. 2002
    ..This article reports an unusual presentation of bowel perforation...
  92. ncbi request reprint Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
    Mathew Simcock
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
    Antivir Ther 12:931-9. 2007
    ..To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma...
  93. ncbi request reprint Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients
    Ladina Joos
    Department of Pulmonary Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Respir Med 101:93-7. 2007
    ..9%, P<0.00001). This study demonstrates a changed pattern of pulmonary infections in immunocompromised patients diagnosed by BAL. The overall diagnostic yield of BAL remains high in immunocompromised patients with respiratory symptoms...
  94. doi request reprint [53 year-old patient with fever and cough]
    C Orasch
    Klinik für Infektiologie and Spitalhygiene, Universitatsspital Basel, Petersgraben 4, 4031, Basel, Schweiz
    Internist (Berl) 50:877-80. 2009
    ..After start of ART, further organ manifestations developed, interpreted as immune reconstitution syndrome. The decision about the optimal time point for starting ART in the presence of an opportunistic infection is essential...
  95. ncbi request reprint [Smoking cessation for HIV infected patients]
    Jacqueline Voggensperger
    Abteilung für Infektiologie, Medizinische Poliklinik, Universitatsspital, Basel, Schweiz
    Pflege 16:283-8. 2003
    ..Practice experiences indicate that the combination of nicotine substitution and counseling in several parts may be a successful interdisciplinary intervention...
  96. doi request reprint Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 53:464-71. 2010
    ..Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited...
  97. doi request reprint Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals
    S Ehrhard
    Institute for Medical Microbiology, University of Basel, Basel, Switzerland
    Infection 36:120-9. 2008
    ..The objective of this study was to investigate the effect of antiretroviral therapy on the lymph node tissue, particularly with respect to morphology and apoptosis...
  98. doi request reprint Eradication of an epidemic methicillin-resistant Staphylococcus aureus (MRSA) from a geriatric university hospital: evidence from a 10-year follow-up
    D Mertz
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Petersgraben 4, Basel, Switzerland
    Eur J Clin Microbiol Infect Dis 29:987-93. 2010
    ..The successful bundle approach for eradication of MRSA during an epidemic is expensive, but the long-term benefits likely outweigh the initial heavy use of resources...
  99. ncbi request reprint Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation
    P Hausermann
    Department of Dermatology, University Hospital Basel, Basel, Switzerland
    Dermatology 208:287-90. 2004
    ..PBL in HIV patients may occur not only in the oral cavity, but can probably involve any other organs including the skin...
  100. ncbi request reprint Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
    H C Bucher
    Basel Center for HIV Research, Internal Medicine Outpatient Clinic University Hospital Basel, Switzerland
    HIV Med 3:247-53. 2002
    ..To compare the response to ritonavir (RTV) plus saquinavir (SQV) with single protease inhibitor (PI) therapies among PI-naive HIV-1 infected individuals...
  101. ncbi request reprint [Diagnostic procedures for patients with community acquired pneumonia]
    U Fluckiger
    Klinik für Infektiologie and Spitalhygiene, Universitatsspital Basel, Petersgraben 4, 4031 Basel
    Internist (Berl) 48:468, 470-2, 474-5. 2007
    ..Recent tests may help in discriminating between viral and bacterial pneumonia (procalcitonin test) or determine the bacteria responsible for acute disease (pneumococcal antigen test using urine)...